April 2019
Intermediate to advanced
480 pages
16h 38m
English
Content preview from High Value Fermentation Products, Volume 1
Become an O’Reilly member and get unlimited access to this title plus top books and audiobooks from O’Reilly and nearly 200 top publishers, thousands of courses curated by job role, 150+ live events each month,
O’Reilly covers everything we've got, with content to help us build a world-class technology community, upgrade the capabilities and competencies of our teams, and improve overall team performance as well as their engagement.I wanted to learn C and C++, but it didn't click for me until I picked up an O'Reilly book. When I went on the O’Reilly platform, I was astonished to find all the books there, plus live events and sandboxes so you could play around with the technology.I’ve been on the O’Reilly platform for more than eight years. I use a couple of learning platforms, but I'm on O'Reilly more than anybody else. When you're there, you start learning. I'm never disappointed.I'm always learning. So when I got on to O'Reilly, I was like a kid in a candy store. There are playlists. There are answers. There's on-demand training. It's worth its weight in gold, in terms of what it allows me to do.
Chapter 7Advances in Production of Therapeutic Monoclonal Antibodies
Richi V Mahajan, Subhash Chand, Mahendra Pal Singh, Apurwa Kestwal and Surinder Singh*
National Institute of Biologicals (Ministry of Health & Family Welfare) Government of India Plot No.A-32, Sector-62 Institutional Area, NOIDA, (U.P.), (India)
*Corresponding author: surinder2560@gmail.com
Abstract
Monoclonal antibodies (mAbs) are target-specific protein therapeutics used by patients suffering from cancer, communicable and autoimmune diseases etc. mAb-based therapeutics have grown exponentially with the advent of mammalian cell culture processes and formulation technology. The mAbtherapeutics market is expected to be US$245.8 billion by 2024. A large number of mAbs have been patented for therapeutic use by the US Food and Drug Administration (FDA) or the European Union health authorities. In the last three decades, various powerful techniques such as hybridoma technology, phage display and B-cell amplification with the help of PCR have been developed for the construction of numerous types of antibodies and antibody fragments with widespread structural modifications. The current review chapter highlights the structure and nomenclature of mAbs, upstream strategies and techniques for cost-effective production of mAbs and recent advances in antibody technology.
Keywords: Monoclonal antibodies, production, hybridoma, phage-display
7.1 Introduction
Monoclonal antibodies (mAbs) are the fast-emerging class of biomolecules, ...
Become an O’Reilly member and get unlimited access to this title plus top books and audiobooks from O’Reilly and nearly 200 top publishers, thousands of courses curated by job role, 150+ live events each month,
and much more.
Read now
Unlock full access
More than 5,000 organizations count on O’Reilly
O’Reilly covers everything we've got, with content to help us build a world-class technology community, upgrade the capabilities and competencies of our teams, and improve overall team performance as well as their engagement.Julian F.
I wanted to learn C and C++, but it didn't click for me until I picked up an O'Reilly book. When I went on the O’Reilly platform, I was astonished to find all the books there, plus live events and sandboxes so you could play around with the technology.Addison B.
I’ve been on the O’Reilly platform for more than eight years. I use a couple of learning platforms, but I'm on O'Reilly more than anybody else. When you're there, you start learning. I'm never disappointed.Amir M.
I'm always learning. So when I got on to O'Reilly, I was like a kid in a candy store. There are playlists. There are answers. There's on-demand training. It's worth its weight in gold, in terms of what it allows me to do.